Citations

Clear

355 citation(s) found for "Sherman, ME".

New horizons in advancing lifestyle medicine for older adults utilizing a transdisciplinary approach: gaps and opportunities
Lassell, Rebecca , Pritchard, Kevin , Baehr, Laura , Ceïde, Mirnova E. , Jayakody, Oshadi , Lieber, Sarah B. , Loewenthal, Julia , Na, Annalisa , Makris, Una E. , Sherman, Andrea, Wagle, Kamal C. , Andonian, Brian J. , Lassell, Rebecca K F , Sheshadri, Anoop , Makris, Una E , Chatterjee, Sudeshna A, Colón-Semenza, Cristina , Mosher, Christopher L. , Myasoedova, Elena , Wingood, Mariana

Mayo Clinic

Age and Ageing | May 28, 2025 | Volume: 54 | Issue: 6 | Pages: No page available

10.1093/ageing/afaf159 | PMID 40511981 Get It

Abstract Nearly half of premature deaths can be prevented with healthy lifestyle behaviours. However, most older adults do not adhere to established guidelines to promote a healthy lifestyle. We propose a tailored framework of lifestyle medicine that acknowledges the complex contexts and care needs of older adults. The proposed framework of lifestyle medicine for older adults integrates their lived experiences (e.g. social determinants of health, built environment), the 5 M framework of geriatric medicine (i.e. Mind, Mobility, Medications, Multicomplexity, Matters Most) and the six pillars of lifestyle medicine (i.e. nutrition/diet, physical activity/exercise, restorative sleep, stress management, avoidance of risky substances, positive social connections) through a novel transdisciplinary approach. Guided by the updated framework, key gaps and opportunities are presented to advance lifestyle medicine practice, research and policy with the goal of promoting sustained behaviour change and improving the healthspan of older adults.
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
Heinrich, Michael C. , Blay, Jean‐Yves , Gelderblom, Hans , George, Suzanne , Schöffski, Patrick , Mehren, Margaret von , Jones, Robin L. , Kang, Yoon‐Koo , Razak, Albiruni R. Abdul , Attia, Steven , Cesne, Axel Le , Goldstein, David , Sánchez, César , Cox, P. H. , Davis, Erika, Sherman, Matthew L. , Ruiz‐Soto, Rodrigo , Bauer, Sebastian , von Mehren, Margaret , Jones, Robin L , Kang, Yoon-Koo , Razak, Albiruni Abdul , Trent, Jonathan , Attia, Steven , Le Cesne, Axel , Boye, Kjetil , Sánchez, César , Cox, Paulina , Ruiz-Soto, Rodrigo , Bauer, Sebastian , Blay, Jean-Yves , Gelderblom, Hans , Heinrich, Michael C , George, Suzanne , Zalcberg, John , Trent, Jonathan C. , Siontis, Brittany L.

Mayo Clinic

Journal of Clinical Oncology | May 23, 2025 | Volume: 43 | Issue: 20 | Pages: 2239-2244

10.1200/jco-24-02818 | PMID 40408605 Get It

In the INTRIGUE phase III trial (ClinicalTrials.gov identifier: NCT03673501 ), adult patients with advanced gastrointestinal stromal tumor previously treated with imatinib were randomly assigned 1:1 to ripretinib 150 mg once daily or sunitinib 50 mg once daily (4 weeks on/2 weeks off). In the primary analysis, overall survival (OS) was immature. In this study, we report the final planned analysis of OS (key secondary end point), progression-free survival (PFS) on third-line therapy (second PFS; prespecified exploratory end point), and long-term safety. Final OS analysis was prespecified to occur with approximately 200 and ≥145 events in the overall and KIT exon 11 intention-to-treat (ITT) populations, respectively. As of March 15, 2023, there were 211 and 151 OS events in the overall ITT and KIT exon 11 ITT populations, respectively. Median OS was similar between second-line ripretinib and sunitinib in both populations (overall, 35.5 v 31.5 months; KIT exon 11, 35.5 v 32.8 months). Median second PFS (on third-line therapy) for the overall ITT population was similar between the ripretinib and sunitinib arms (7.7 v 7.4 months). Safety was consistent with the primary analysis. OS from this analysis was similar between arms, and second PFS suggests that receiving ripretinib did not adversely affect the PFS of third-line therapy.
Abstract 187: STAT1 and GBP1 promote proliferation in postpartum breast epithelium by downregulating cyclin-dependent kinase inhibitors: implications for increased postpartum breast cancer risk
Ogony, Joshua, McLaughlin, Sarah A. , Sherman, Mark E. , Stallings‐Mann, Melody , Radisky, Derek C.

Mayo Clinic

Cancer Research | April 22, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 187-187

10.1158/1538-7445.am2025-187 Get It

Abstract Background: Postpartum breast cancer (PPBC) is associated with increased morbidity and mortality among women within 5 to 10 years following childbirth. The postpartum breast undergoes involution, involving tissue remodeling and immune cell infiltration, potentially creating a pro-tumorigenic microenvironment. The molecular mechanisms underlying this elevated risk remain poorly understood. In this study, we compared normal breast tissue samples and human mammary epithelial cells (HMECs) from postpartum women to those from age- and BMI-matched nulliparous women to elucidate potential molecular contributors to PPBC risk. Methods: Transcriptomic profiling was performed on RNA extracted from FFPE normal breast tissues using the NanoString IO 360 and BC 360 platforms to examine gene expression in nulliparous and postpartum women under 45 years of age. HMECs were isolated from organoids derived from breast tissue samples and used for next-generation sequencing and knockdown experiments targeting STAT1 and GBP1. Gene set enrichment analysis (GSEA) was applied to NanoString and RNA-seq datasets to identify differentially enriched genes between postpartum and nulliparous women. Results: Transcriptomic analysis revealed significant upregulation of interferon-stimulated genes, including STAT1 and GBP1, in postpartum breast tissues, consistent with increased immune responses during involution. NanoString data showed that markers of cell proliferation, such as Ki67, STAT1, and GBP1, were significantly higher in samples from parous compared to nulliparous women (p < 0.05). GSEA revealed that cell cycle-promoting genes (GBP1, cyclins, CDKs) were upregulated, while cyclin-dependent kinase inhibitors (CDKNs) were downregulated in postpartum breast tissues. Immunohistochemistry confirmed significantly higher expression of Ki67, STAT1, and GBP1 in postpartum versus nulliparous breast tissues (p < 0.0001). Silencing STAT1 and GBP1 in HMECs resulted in decreased cell proliferation, G1 cell cycle arrest, and increased expression of CDKN1A and CDKN1C. Conclusion: These findings suggest that STAT1 and GBP1 promote proliferation in postpartum breast epithelial cells by downregulating cyclin-dependent kinase inhibitors, potentially contributing to the increased risk of PPBC. Targeting these pathways may offer novel strategies for mitigating postpartum breast cancer risk. Citation Format: Joshua Ogony, Melody Stallings-Mann, Sarah McLaughlin, Mark Sherman, Derek C. Radisky. STAT1 and GBP1 promote proliferation in postpartum breast epithelium by downregulating cyclin-dependent kinase inhibitors: implications for increased postpartum breast cancer risk [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 187.
Abstract 2083: Activated fibroblasts in benign breast tissue are associated with subsequent breast cancer development
Cruz-Reyes, Nicole , Westerman, Pria, Rossi, Matilde , Erak, Camila Pacheco, Mann, Melody Stallings, McCauley, Bryan M. , Sherman, Mark E. , Westerman, Pria, Vierkant, Robert A. , Winham, Stacey J. , Degnim, Amy C. , Radisky, Derek C.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2083-2083

10.1158/1538-7445.am2025-2083 Get It

Abstract Introduction: Pseudoangiomatous stromal hyperplasia (PASH) is a benign breast lesion characterized by stromal myofibroblast accumulation. While most women with PASH do not develop breast cancer, a subset eventually does, often in the same breast where PASH was originally diagnosed, even after surgical removal of the lesion. This pattern suggests the presence of a field effect, where alterations in the PASH microenvironment extend beyond the lesion itself, potentially influencing neighboring breast tissue. This study aims to identify specific fibroblasts within PASH-containing tissues that may create a microenvironment conducive to cancer initiation. Methods: We conducted a retrospective analysis of formalin-fixed, paraffin-embedded breast tissue samples from women diagnosed with PASH, comparing those who later developed breast cancer (cases) to those who remained cancer-free (controls). Using transcriptional profiling with NanoString IO360/BC360 panels, multiplex immunofluorescence (MxIF), and spatial transcriptomics via NanoString CosMX SMI, we investigated molecular and histopathological differences. We focused on the expression of fibroblast activation markers (ITGB1, PDGFRβ) and their spatial relationships with proliferating epithelial cells, as well as changes in extracellular matrix (ECM) composition and stiffness. Results: Transcriptional profiling revealed significant upregulation of proliferation-associated genes in epithelial cells from cases. MxIF showed higher Ki-67 levels in epithelial cells from cases, with proliferating cells forming clustered regions. Activated fibroblasts expressing ITGB1 and PDGFRβ were markedly increased in cases and were located closer to proliferating epithelial cells. Spatial transcriptomics uncovered gene expression changes in fibroblasts indicative of an activated phenotype, and in epithelial cells, consistent with responses to increased tissue stiffness and mechanotransduction signaling. Polarized light imaging with picrosirius red staining revealed enhanced collagen cross-linking and thick fibril formation in cases, indicating greater ECM stiffness. Conclusions: Our findings suggest that a subset of activated fibroblasts in benign breast tissue creates a pro-tumorigenic microenvironment through ECM remodeling and increased tissue stiffness, promoting epithelial proliferation and potentially driving cancer development. The spatial proximity of these fibroblasts to proliferating epithelial cells underscores their possible role in early carcinogenesis. This study introduces the novel concept of cancer-predisposing fibroblasts in benign breast tissue, providing new insights into microenvironmental changes that precede cancer and offering potential targets for early detection and intervention. Citation Format: Nicole Cruz-Reyes, Pria Westerman, Matilde Rossi, Camila Pacheco Erak, Melody Stallings Mann, Bryan McCauley, Robert Vierkant, Stacey Winham, Mark Sherman, Amy Degnim, Derek Radisky. Activated fibroblasts in benign breast tissue are associated with subsequent breast cancer development [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2083.
Abstract 2077: Elevated PI16 expression in fibroadenoma fibroblasts is associated with subsequent breast cancer development
Westerman, Pria, Cruz-Reyes, Nicole , Erak, Camila Pacheco, McCauley, Bryan M. , Sherman, Mark E. , Westerman, Pria, Vierkant, Robert A. , Winham, Stacey J. , Degnim, Amy C. , Radisky, Derek C.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2077-2077

10.1158/1538-7445.am2025-2077 Get It

Abstract Introduction: Fibroadenoma is the most common type of benign breast lesion and is not traditionally considered an indicator of increased breast cancer risk. This study aimed to identify biomarkers within fibroadenoma associated with subsequent breast cancer development using patient samples from the Mayo Clinic Benign Breast Disease (BBD) cohort. Methods: We analyzed formalin-fixed paraffin-embedded (FFPE) breast biopsy samples from patients diagnosed with non-proliferative fibroadenoma who either developed breast cancer later (n=10) or remained cancer-free (n=5). NanoString RNA profiling identified differentially expressed genes in fibroblasts associated with subsequent cancer development. Immunohistochemistry was first done to compare overall expression of PI16 in this cohort. Opal multiplex immunofluorescence staining (mIF) was then performed to evaluate the expression of PI16 in fibroblasts (Vim+PanCK-) and assess immune cell infiltration (CD45+) in different tissue compartments. Fibroblasts were identified by vimentin positivity (Vim+), and epithelial cells were marked by pan-cytokeratin positivity (PanCK+). Results: Compared to patients who remained cancer-free, those who developed breast cancer showed significantly increased expression of PI16 in fibroblasts (PI16+Vim+PanCK-, 3.25-fold increase, p=0.0011). Additionally, the number of immune cells (CD45+) was significantly decreased (0.52-fold, p=0.03) in the fibroadenoma lesions of patients who later developed cancer. Conclusions: Our findings suggest that elevated expression of PI16 in fibroblasts within fibroadenoma may serve as potential biomarkers for predicting breast cancer risk for women with fibroadenoma. PI16 encodes Peptidase Inhibitor 16, which is implicated in modulating fibroblast activity and extracellular matrix remodeling—processes that can contribute to a tumor-supportive microenvironment. Elevated levels of this protein in fibroblasts suggest an altered microenvironment that may foster tumor initiation and progression. The decreased immune cell infiltration further implies an immunosuppressive microenvironment that may facilitate cancer progression. As these markers can be detected in FFPE samples, our results could lead to the development of a readily applicable clinical test to identify fibroadenoma patients at increased risk for breast cancer, enabling earlier intervention and surveillance. Citation Format: Pria Westerman, Nicole Cruz-Reyes, Camila Pacheco Erak, Robert Vierkant, Bryan McCauley, Stacey Winham, Mark Sherman, Amy Degnim, Derek Radisky. Elevated PI16 expression in fibroadenoma fibroblasts is associated with subsequent breast cancer development. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2077.
Abstract 1912: Immune and molecular markers in benign breast disease predict risk of node-positive breast cancer
Rossi, Matilde , Cruz-Reyes, Nicole , Navarro, Trista, McCauley, Bryan M. , Stallings‐Mann, Melody , Vierkant, Robert A. , Winham, Stacey J. , Sherman, Mark E. , Degnim, Amy C. , Radisky, Derek C.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 1912-1912

10.1158/1538-7445.am2025-1912 Get It

Abstract Background: Breast cancer (BC) remains a leading health concern worldwide and is often undetected until it metastasizes, limiting treatment options and worsening prognosis. Early detection of molecular and immune markers in benign breast disease (BBD) could identify women at elevated risk of developing invasive, node-positive BC, enabling targeted surveillance and prevention efforts. Building on this premise, we investigated the immune and molecular landscape of BBD biopsies preceding BC development to enhance risk stratification and inform preventive strategies. Methods: Utilizing the Mayo Clinic BBD cohort, we conducted a case-control study comparing women who developed node-positive BC following their BBD biopsy (cases; n=8) to those who remained cancer-free (controls; n=11), matched on patient age and biopsy date. Differential gene expression was assessed using the NanoString nCounter system to identify differentially expressed genes between cases and controls. We developed a multiplex immunofluorescence (MxIF) approach using the Opal system by Akoya Biosciences for comprehensive marker detection in formalin-fixed, paraffin-embedded (FFPE) tissue samples. Digitized images were segmented for cell phenotyping, and spatial relationships of immune cells were analyzed and compared between cases and controls. Results: Our findings revealed significantly increased expression levels of immunosuppressive genes in the case group, including CD48, CD84, IL-32, and LAIR1. Immunohistochemical analyses showed that controls exhibited higher frequencies of CD68+ (macrophages), CD11c+ (M1 macrophages), and CD206+ (M2 macrophages) cells compared to cases. Notably, controls had a significant increase in CD68+CD11c+ cells, indicative of a pro-inflammatory, antitumorigenic M1 macrophage polarization. Furthermore, our MxIF analyses provided novel insights into spatial biomarker localization, enhancing prognostic accuracy. Conclusions: The decreased numbers of immune cells and increased expression of immunosuppressive genes in BBD biopsies may be associated with an elevated risk of developing axillary node-positive BC. These findings emphasize the importance of dissecting molecular and immune interactions in BBD for risk assessment. Our results have the potential to improve individualized risk stratification, leading to more targeted surveillance and informed screening. This research not only contributes to our understanding of BC pathogenesis but also opens avenues for developing novel preventive strategies, potentially reducing BC incidence and mortality through early intervention. Citation Format: Matilde Rossi, Nicole Cruz-Reyes, Trista Navarro, Melody L. Stallings-Mann, Bryan M. McCauley, Robert A. Vierkant, Stacey J. Winham, Mark E. Sherman, Amy C. Degnim, Derek C. Radisky. Immune and molecular markers in benign breast disease predict risk of node-positive breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1912.
WITHDRAWN: Spatial Analysis of Placentae During Congenital Cytomegalovirus Infection Reveals Distinct Cellular Profiles in Immune Cells and Trophoblasts
Sintim-Aboagye, Elise, Sherman, W.B., Farnan, Sheila, Otrubova, Kamila, Verma, N, Littlefield, Dawn, Punia, Sohan, Blackstad, Mark, Schleiss, Mark R. , Enninga, Elizabeth Ann L. , Chakraborty, Rana , Quach, Huy Quang , Sherman, Will, Verma, Namisha, Schleiss, Mark R , Enninga, Elizabeth Ann L , Sherman, Will, Verma, Namisha, Johnson, Erica L. , Norgan, Andrew P. , Gray, Clive M.

Mayo Clinic

No container title available | April 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.04.04.647170 | PMID 40291677 Get It

Withdrawal Statement The authors have withdrawn the manuscript because the data it contained has been updated. Consequently, they request that this work should not be cited as a reference for any projects to ensure the use of the most current information. For any questions or further clarifications, readers are encouraged to contact the corresponding author directly
EEG as a Predictive Tool for Seizures and Survival Outcomes Related to CAR T-cell Therapy (P3-9.002)
Chiriboga, Guido , Pecha, Thomas, Shar, Andy , Betiku, Oluwatoni, Drees, Cornelia , Sherman, Wendy, Tatum, William O. , Freund, Brin , Pecha, Thomas A., Betiku, O. A., Feyissa, Anteneh M. , Drees, Cornelia , Qin, Hong, Britton, Jeffrey W. , ReFaey, Karim

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000212200 Get It

Acute Symptomatic Seizures During CAR T-Cell Therapy for Hematologic Malignancies: Tri-Site Mayo Clinic Experience (S20.003)
Freund, Brin , Shar, Andy , Betiku, O. A., Drees, Cornelia , Barrios, M. A. , Tatum, William O. , Feyissa, Anteneh M. , Drees, Cornelia , Sherman, Wendy , Qin, Hong , Britton, Jeffrey W. , Barrios, Maria, ReFaey, Karim

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211534 Get It